Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
Pipe, Steven W.; Hermans, Cédric; Chitlur, Meera; Carcao, Manuel; Castaman, Giancarlo; Davis, Joanna A.; Ducore, Jonathan; Dunn, Amy L.; Escobar, Miguel; Journeycake, Janna; Khan, Osman; Mahlangu, Johnny; Meeks, Shannon L.; Mitha, Ismail Haroon; Négrier, Claude; Nowak-Göttl, Ulrike; Recht, Michael; Chrisentery-Singleton, Tammuella; Stasyshyn, Oleksandra; Vilchevska, Kateryna V.; Martinez, Laura Villarreal; Wang, Michael; Windyga, Jerzy; Young, Guy; Alexander, W. Allan; Bonzo, Daniel; Macie, Christopher; Mitchell, Ian S.; Sauty, Evelyne; Wilkinson, Thomas A.; Shapiro, Amy D.
2022-07
Citation
Pipe, Steven W.; Hermans, Cédric ; Chitlur, Meera; Carcao, Manuel; Castaman, Giancarlo; Davis, Joanna A.; Ducore, Jonathan; Dunn, Amy L.; Escobar, Miguel; Journeycake, Janna; Khan, Osman; Mahlangu, Johnny; Meeks, Shannon L.; Mitha, Ismail Haroon; Négrier, Claude ; Nowak-Göttl, Ulrike ; Recht, Michael; Chrisentery-Singleton, Tammuella ; Stasyshyn, Oleksandra; Vilchevska, Kateryna V.; Martinez, Laura Villarreal; Wang, Michael; Windyga, Jerzy; Young, Guy; Alexander, W. Allan; Bonzo, Daniel; Macie, Christopher; Mitchell, Ian S.; Sauty, Evelyne; Wilkinson, Thomas A.; Shapiro, Amy D. (2022). "Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors." Haemophilia 28(4): 548-556.
Abstract
IntroductionEptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older.AimTo prospectively assess in a phase 3 clinical trial (PERSEPT 2) eptacog beta efficacy and safety for treatment of bleeding in children <12 years of age with haemophilia A or B with inhibitors.MethodsUsing a randomised crossover design, subjects received initial doses of 75 or 225 μg/kg eptacog beta followed by 75 μg/kg dosing at predefined intervals (as determined by clinical response) to treat bleeding episodes (BEs). Treatment success criteria included a haemostasis evaluation of ‘excellent’ or ‘good’ without use of additional eptacog beta, alternative haemostatic agent or blood product, and no increase in pain following the first ‘excellent’ or ‘good’ assessment.ResultsTreatment success proportions in 25 subjects (1–11 years) who experienced 546 mild or moderate BEs were 65% in the 75 μg/kg initial dose regimen (IDR) and 60% in the 225 μg/kg IDR 12 h following initial eptacog beta infusion. By 24 h, the treatment success proportions were 97% for the 75 μg/kg IDR and 98% for the 225 μg/kg IDR. No thrombotic events, allergic reactions, neutralising antibodies or treatment-related adverse events were reported.ConclusionBoth 75 and 225 μg/kg eptacog beta IDRs provided safe and effective treatment and control of bleeding in children <12 years of age.Publisher
National Hemophilia Foundation Wiley Periodicals, Inc.
ISSN
1351-8216 1365-2516
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.